Permax: profile and news

DRAXIS Health Reports Results for the First Quarter of 2006 May 11, 2006
In July 2005, a claim was filed before the Ontario Superior Court of Justice against the Company together with other defendants alleging that Permax®, a drug ... - Yahoo! News (press release)

Other information

Indication
Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson’s disease.

Pharmacology
Pergolide is an ergot derivative dopamine receptor agonist at both D1 and D2 receptor sites. Pergolide is 10 to 1,000 times more potent than bromocriptine on a milligram per milligram basis in various in vitro and in vivo test systems. Pergolide mesylate inhibits the secretion of prolactin in humans; it causes a transient rise in serum concentrations of growth hormone and a decrease in serum concentrations of luteinizing hormone. In Parkinson’s disease, pergolide mesylate is believed to exert its therapeutic effect by directly stimulating postsynaptic dopamine receptors in the nigrostriatal system.

Mechanism Of Action
Pergolide is a potent dopamine receptor agonist. It directly stimulates post-synaptic dopamine receptors at both D1 and D2 receptor sites in the nigrostriatal system.

Drug Category
Neuroprotective Agents; Antiparkinson Agents; Antidyskinetics; Dopamine Agonists; Central Nervous System Agents; ATC:N04BC02

Brand Names/Synonyms
PERGOLIDE; Pergolida [Inn-Spanish]; Pergolide; Pergolide Mesylate; Pergolide Methanesulfonate; Pergolidum [Inn-Latin]; Permax

Dosage Forms
TABLET

Absorption
Significant amount may be absorbed (evidence on bioavailability still lacking).

Interactions
Interactions for Pergolide:

Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); these agents may diminish the effectiveness of Permax. Because pergolide mesylate is approximately 90% bound to plasma proteins, caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding.

Chemical IUPAC Name
Not Available

Chemical Formula
C19H26N2S

Half Life
Not Available

Drug Type
Approved Drug

# Accession No
APRD00663

CAS Registry Number
66104-22-1